<DOC>
	<DOC>NCT01001715</DOC>
	<brief_summary>Primary objective was to demonstrate the activity of REGN475/SAR164877 in reducing the pain associated with vertebral fracture. Secondary objectives were: - to assess the safety and tolerability of REGN475/SAR164877 in patients with vertebral fracture pain; - to characterize the pharmacokinetic and immunogenicity profiles of REGN475/SAR164877 in this population.</brief_summary>
	<brief_title>Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain</brief_title>
	<detailed_description>The duration of the study period for each participant was up to 13 weeks, including a screening period up to 5 days, and 12-week follow-up after the injection.</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<criteria>Inclusion criteria: Moderate to severe pain due to nontraumatic vertebral fracture associated with osteoporosis. Exclusion criteria: Mild pain score on the Pain IntensityNumeric Rating Scale [PINRS] at screening and randomization visits; Narcotic addiction; Postfracture vertebral instability; Unwillingness to use studydefined rescue analgesia exclusively. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>